bioMérieux (BIM) Stock Overview
Develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
BIM Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
bioMérieux S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €67.30 |
| 52 Week High | €128.30 |
| 52 Week Low | €66.25 |
| Beta | 0.56 |
| 1 Month Change | -8.19% |
| 3 Month Change | -25.35% |
| 1 Year Change | -44.38% |
| 3 Year Change | -25.47% |
| 5 Year Change | -28.99% |
| Change since IPO | 573.00% |
Recent News & Updates
Analysis Article • Jun 22
bioMérieux (ENXTPA:BIM) Stock Could Be 23.7% Undervalued After Salmonella Test Launch
bioMérieux (ENXTPA:BIM) has launched GENE-UP TYPER SLM, a patented real-time PCR assay that helps food manufacturers quickly discriminate Salmonella enterica subspecies enterica and trace contamination sources through a machine learning powered web application. See our latest analysis for bioMérieux. Despite the product launch, bioMérieux’s recent share price performance has been weak. The stock is at €69.0, with a 90 day share price return that declined 23.93% and a 1 year total shareholder...
Narrative Update • Jun 12
BIM: Fast Sepsis Diagnostics And PCR Capacity Will Support Future Returns
Analysts have trimmed their average price target for bioMérieux by about €6 per share. This reflects slightly softer revenue growth assumptions, a modestly lower future P/E and a small adjustment to the discount rate, even as profit margin expectations edge higher.Narrative Update • May 29
BIM: Fast Sepsis And Food Diagnostics Will Support Future Returns
bioMérieux’s analyst price target has been revised lower to about €96.51, down from roughly €104.47, as analysts factor in slightly softer assumptions for revenue growth, profit margins, and future P/E multiples following recent target cuts at several banks. Analyst Commentary Bullish Takeaways Bullish analysts still see value in bioMérieux’s diagnostics portfolio, suggesting the business profile can support a premium to some peers even after the price target cuts.
New Narrative • May 01
Point Of Care Expansion And Efficiency Program Will Transform Long Term Earnings Profile
Catalysts About bioMérieux bioMérieux develops and supplies in vitro diagnostic solutions for clinical and industrial customers worldwide. What are the underlying business or industry changes driving this perspective?Recent updates
Analysis Article • Jun 22
bioMérieux (ENXTPA:BIM) Stock Could Be 23.7% Undervalued After Salmonella Test Launch
bioMérieux (ENXTPA:BIM) has launched GENE-UP TYPER SLM, a patented real-time PCR assay that helps food manufacturers quickly discriminate Salmonella enterica subspecies enterica and trace contamination sources through a machine learning powered web application. See our latest analysis for bioMérieux. Despite the product launch, bioMérieux’s recent share price performance has been weak. The stock is at €69.0, with a 90 day share price return that declined 23.93% and a 1 year total shareholder...Narrative Update • Jun 12
BIM: Fast Sepsis Diagnostics And PCR Capacity Will Support Future Returns
Analysts have trimmed their average price target for bioMérieux by about €6 per share. This reflects slightly softer revenue growth assumptions, a modestly lower future P/E and a small adjustment to the discount rate, even as profit margin expectations edge higher.Narrative Update • May 29
BIM: Fast Sepsis And Food Diagnostics Will Support Future Returns
bioMérieux’s analyst price target has been revised lower to about €96.51, down from roughly €104.47, as analysts factor in slightly softer assumptions for revenue growth, profit margins, and future P/E multiples following recent target cuts at several banks. Analyst Commentary Bullish Takeaways Bullish analysts still see value in bioMérieux’s diagnostics portfolio, suggesting the business profile can support a premium to some peers even after the price target cuts.New Narrative • May 01
Point Of Care Expansion And Efficiency Program Will Transform Long Term Earnings Profile
Catalysts About bioMérieux bioMérieux develops and supplies in vitro diagnostic solutions for clinical and industrial customers worldwide. What are the underlying business or industry changes driving this perspective?Narrative Update • Apr 25
BIM: Food And Sepsis Diagnostics Expansion Will Support Future Returns
Analysts have trimmed their price targets on bioMérieux, with the updated fair value estimate moving from about €116.04 to roughly €104.47 as they factor in lower revenue growth, a slightly higher discount rate, and a modestly reduced future P/E. Analyst Commentary Recent Street research on bioMérieux has leaned more cautious, with several firms revisiting their assumptions on growth, execution and valuation.
New Narrative • Apr 15
Microbiology Automation And Efficiency Program Will Support Stable Prospects Despite Competitive Pressures
Catalysts About bioMérieux bioMérieux develops and supplies in vitro diagnostic solutions for clinical and industrial applications worldwide. What are the underlying business or industry changes driving this perspective?Narrative Update • Apr 09
BIM: Food Diagnostics Expansion And Dividend Support Will Drive Future Returns
Analyst price targets for bioMérieux have been revised lower to €100. This reflects a slightly reduced fair value estimate and Street research pointing to more cautious views on the shares, while still assuming broadly unchanged revenue growth, profit margin and P/E expectations.Narrative Update • Mar 25
BIM: Food Diagnostics Expansion And Cost Discipline Will Support Future Returns
bioMérieux’s updated analyst price target moves to €100 from €110, reflecting recent Street revisions as analysts reassess assumptions on growth, margins, and forward P/E multiples. Analyst Commentary Bullish Takeaways Bullish analysts see the revised €100 target as aligning the share price more closely with current assumptions on growth and margins, which they view as better grounded than prior expectations at €110.Analysis Article • Mar 25
There May Be Reason For Hope In bioMérieux's (EPA:BIM) Disappointing Earnings
bioMérieux S.A.'s ( EPA:BIM ) stock was strong despite it releasing a soft earnings report last week. Our analysis...Narrative Update • Mar 10
BIM: Food Diagnostics Expansion And Higher Margins Will Support Future Returns
Narrative Update Analysts have trimmed their fair value estimate for bioMérieux to €116.50 from €119.12, reflecting lower Street price targets along with updated assumptions for revenue growth, margins and future P/E multiples. Analyst Commentary Recent research updates point to a more cautious stance on bioMérieux, with several firms trimming price targets and one downgrade.Narrative Update • Feb 23
BIM: Equine And Food Diagnostics Expansion Will Support Future Margins
Analysts have trimmed their price target on bioMérieux by €3, reflecting slightly more cautious assumptions on the discount rate, revenue growth, and profit margins following recent research updates from major banks. Analyst Commentary Recent Street research on bioMérieux points to a more measured stance from both bullish and bearish analysts, with price targets being adjusted to reflect updated views on risk, growth, and profitability.Analysis Article • Feb 10
The Price Is Right For bioMérieux S.A. (EPA:BIM)
When close to half the companies in France have price-to-earnings ratios (or "P/E's") below 16x, you may consider...Narrative Update • Feb 08
BIM: Equine Diagnostics Expansion Will Support Future Margins Despite Recent Caution
Analysts have trimmed their fair value estimate for bioMérieux by about €3 to €119.12 per share. This reflects slightly softer assumptions on revenue growth and margins after recent price target cuts and a downgrade in Street research.Narrative Update • Jan 24
BIM: Expanding Veterinary Diagnostics Will Support Future Margin Strength And Rerating Potential
Analysts have trimmed their price expectations for bioMérieux, with the consensus fair value edging from about €125.18 to €122.27, in line with a recent move in Street targets, including a cut in one major bank's price target to €113 from €120, as they factor in slightly more conservative assumptions on growth, margins and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts highlight that a consensus fair value close to €122,27 still sits above the latest major price target of €113, which they see as leaving some room for rerating if execution on growth and margins matches expectations.Analysis Article • Jan 20
Estimating The Fair Value Of bioMérieux S.A. (EPA:BIM)
Key Insights bioMérieux's estimated fair value is €96.28 based on 2 Stage Free Cash Flow to Equity bioMérieux's €104...Narrative Update • Dec 26
BIM: Expanding Veterinary Diagnostics Will Support Future Margin Strength And Upside Potential
Analysts have slightly trimmed their price target on bioMérieux, reflecting a modest recalibration of fair value to about €125.18 from €125.25. They cite recent target cuts and a more cautious outlook embedded in their updated growth and discount rate assumptions.Narrative Update • Dec 12
BIM: Rising Margins And Veterinary Expansion Will Support Stronger Share Performance
Analysts have modestly raised their fair value estimate for bioMérieux to approximately €125 from about €123, despite a recent reduction in a key Street price target to €113. They cited a slightly higher discount rate, more conservative revenue growth assumptions, and a small improvement in expected profit margins and valuation multiples.Analysis Article • Dec 01
Here's What To Make Of bioMérieux's (EPA:BIM) Decelerating Rates Of Return
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things...Analysis Article • Nov 10
Is bioMérieux (EPA:BIM) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Oct 05
What You Can Learn From bioMérieux S.A.'s (EPA:BIM) P/E
When close to half the companies in France have price-to-earnings ratios (or "P/E's") below 16x, you may consider...Analysis Article • Sep 12
bioMérieux's (EPA:BIM) Conservative Accounting Might Explain Soft Earnings
Shareholders appeared unconcerned with bioMérieux S.A.'s ( EPA:BIM ) lackluster earnings report last week. Our analysis...Analysis Article • Sep 06
Is bioMérieux S.A. (EPA:BIM) Worth €118 Based On Its Intrinsic Value?
Key Insights bioMérieux's estimated fair value is €95.71 based on 2 Stage Free Cash Flow to Equity Current share price...
New Narrative • Feb 09
FDA Approvals And Expansion Of Installed Base Will Drive Future Success
bioMérieux's strategic plan targets high growth in organic sales and EBIT, with improvements in revenue and net margins by enhancing operational efficiencies.Shareholder Returns
| BIM | FR Medical Equipment | FR Market | |
|---|---|---|---|
| 7D | -0.2% | -5.0% | 0.07% |
| 1Y | -44.4% | -29.5% | 7.3% |
Return vs Industry: BIM underperformed the French Medical Equipment industry which returned -29.5% over the past year.
Return vs Market: BIM underperformed the French Market which returned 7.3% over the past year.
Price Volatility
| BIM volatility | |
|---|---|
| BIM Average Weekly Movement | 6.3% |
| Medical Equipment Industry Average Movement | 6.9% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in FR Market | 11.1% |
| 10% least volatile stocks in FR Market | 2.7% |
Stable Share Price: BIM has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: BIM's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1963 | 14,894 | Pierre Boulud | www.biomerieux.com |
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL, a rapid AST system; ETEST, a gradient method on culture media; BIOMERIEUX EPISEQ CS, a whole genome sequencing solution for epidemiologic monitoring; VIDAS, a specific marker of severe bacterial infections/sepsis; and Biomérieux vision suite, a software that provides information to support diagnosis and clinical decision making.
bioMérieux S.A. Fundamentals Summary
| BIM fundamental statistics | |
|---|---|
| Market cap | €8.14b |
| Earnings (TTM) | €397.50m |
| Revenue (TTM) | €4.07b |
20.0x
P/E Ratio2.0x
P/S RatioIs BIM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIM income statement (TTM) | |
|---|---|
| Revenue | €4.07b |
| Cost of Revenue | €1.76b |
| Gross Profit | €2.31b |
| Other Expenses | €1.91b |
| Earnings | €397.50m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Jul 28, 2026
| Earnings per share (EPS) | 3.37 |
| Gross Margin | 56.73% |
| Net Profit Margin | 9.77% |
| Debt/Equity Ratio | 7.6% |
How did BIM perform over the long term?
See historical performance and comparisonDividends
1.5%
Current Dividend Yield29%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/22 01:22 |
| End of Day Share Price | 2026/06/22 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
bioMérieux S.A. is covered by 28 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gaurav Jain | Barclays |
| Charles Pitman | Barclays |
| Thomas Jones | Berenberg |